Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: February 5, 2003
Last updated: June 18, 2013
Last verified: July 2004

RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.

PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with interleukin-2 in treating patients who have metastatic melanoma.

Condition Intervention Phase
Melanoma (Skin)
Biological: aldesleukin
Biological: recombinant fowlpox-tyrosinase vaccine
Biological: vaccinia-tyrosinase vaccine
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Treatment Of Patients With Metastatic Melanoma Using Recombinant Vaccinia And Fowlpox Viruses Encoding The Tyrosine Antigen In Combination With Interleukin-2

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: January 2003
Study Completion Date: September 2004
Detailed Description:


  • Determine the response rate (partial response or complete remission) in patients with metastatic melanoma treated with vaccinia-tyrosinase vaccine, fowlpox-tyrosinase vaccine, and high-dose interleukin-2.
  • Determine the immunologic response, measured by the reactivity of CD4+ and CD8+ T cells and serum immunoglobulins against tyrosinase and melanoma cells, in patients treated with this regimen.

OUTLINE: Patients receive vaccinia-tyrosinase vaccine intramuscularly (IM) on day 1 followed by fowlpox-tyrosinase vaccine IM on days 15 and 29. Patients then receive high-dose interleukin-2 (IL-2) IV over 15 minutes every 8 hours beginning on day 30 for up to 12 doses and again beginning approximately 3 weeks after the initial dose. Patients with stable disease or a minor, mixed, or partial response may receive additional courses of fowlpox-tyrosinase vaccine (2 doses) and IL-2 as above in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 1 additional course beyond achieving CR.

Patients are followed annually for at least 5 years.

PROJECTED ACCRUAL: A total of 19-35 patients will be accrued for this study within 2 years.


Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Diagnosis of metastatic melanoma

    • Measurable disease
    • Disease progression while receiving prior standard treatment
    • No ocular or mucosal primary site
  • No uncontrolled brain metastases



  • 16 and over

Performance status

  • ECOG 0-1

Life expectancy

  • More than 3 months


  • WBC at least 3,000/mm^3
  • Platelet count at least 90,000/mm^3
  • No coagulation disorders


  • Bilirubin no greater than 1.6 mg/dL (less than 3.0 mg/dL in patients with Gilbert's syndrome)
  • AST/ALT less than 3 times normal
  • Hepatitis B surface antigen negative
  • Hepatitis C antibody negative


  • Creatinine no greater than 1.6 mg/dL


  • No major cardiovascular illness


  • No major respiratory illness


  • HIV negative
  • No autoimmune disease
  • No active systemic infections
  • No primary or secondary immunodeficiency (e.g., hereditary disorders such as ataxia-telangiectasia or Wiskott-Aldrich syndrome or acquired immunodeficiencies after bone marrow transplantation)
  • No allergy to eggs
  • No prior allergy or untoward reaction to smallpox vaccination (if previously vaccinated)


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No close contact with the following individuals for 2 weeks after vaccinia vaccination:

    • Children under 5 years of age
    • Pregnant women
    • Individuals with prior or active eczema or other eczematoid skin disorders
    • Individuals with other acute, chronic, or exfoliative skin conditions (e.g., burns, impetigo, varicella zoster, severe acne, or other open rashes or wounds)
    • Immunosuppressed individuals
  • No active atopic dermatitis
  • No prior or active eczema
  • No active cases of the following conditions:

    • Extensive psoriasis
    • Severe acneiform rash
    • Impetigo
    • Varicella zoster
    • Burns
    • Traumatic or pruritic skin conditions
    • Open wounds
  • No unhealed surgical scars

    • Healed surgical stomas (e.g., colostomy) allowed


Biologic therapy

  • No prior recombinant vaccinia or fowlpox vaccines for melanoma
  • No prior vaccination with full length tyrosinase protein, or a vector encoding the full length protein for melanoma

    • Prior individual tyrosinase peptides are allowed
  • No prior high-dose interleukin-2


  • Not specified

Endocrine therapy

  • No concurrent oral, IV, topical, or inhaled steroids


  • Not specified


  • Recovered from prior surgery


  • Recovered from prior therapy for melanoma
  • More than 3 weeks since prior systemic therapy for melanoma
  • No other concurrent systemic therapy for melanoma
  Contacts and Locations
Please refer to this study by its identifier: NCT00054535

United States, Maryland
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Bethesda, Maryland, United States, 20892-1182
Sponsors and Collaborators
Study Chair: Suzanne L. Topalian, MD NCI - Surgery Branch
  More Information

Additional Information:
No publications provided Identifier: NCT00054535     History of Changes
Obsolete Identifiers: NCT00051610
Other Study ID Numbers: CDR0000270794, NCI-03-C-0080, NCI-6119
Study First Received: February 5, 2003
Last Updated: June 18, 2013
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage IV melanoma
recurrent melanoma

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Agents
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents processed this record on April 20, 2014